Clinical Trials on Psoriatic Nail in Hungary

Total 136 results

Janssen Research & Development, LLC

Completed

An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age (CADMUS Jr)

Psoriasis

United States, Germany, Taiwan, Belgium, Korea, Republic of, Canada, Poland, Hungary, Netherlands
Pfizer

Completed

Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept (ReSPONSE)

Psoriasis

Spain, France, Germany, Turkey, United Kingdom, Hungary, Greece, Italy, United Arab Emirates
Bausch Health Americas, Inc.

Terminated

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis (AMAGINE-2)

Moderate to Severe Plaque Psoriasis

United States, Austria, France, Poland, Australia, Czechia, Canada, Hungary, Portugal, Spain, Netherlands
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis (FIXTURE)

Chronic Plaque Psoriasis

Germany, United States, Colombia, Italy, Spain, Belgium, Egypt, Hungary, Australia, Singapore, France, Sweden, Guatemala, Philippines, Korea, Republic of, United Kingdom, Argentina, Poland, Romania, Canada, Iceland, India, Finland
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants (PROTOSTAR)

Psoriasis

Belgium, Germany, Netherlands, Hungary, United States, Italy, Australia, Canada, Poland
Novartis Pharmaceuticals

Completed

Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

Chronic Plaque Type Psoriasis

Germany, United States, Belgium, Korea, Republic of, Spain, Taiwan, Australia, Austria, Italy, Estonia, Israel, Bulgaria, Netherlands, France, Switzerland, Portugal, Slovakia, Norway, United Kingdom, Hungary, Turkey, Canada, Denmark, ...
Novartis Pharmaceuticals

Completed

Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

Moderate to Severe Chronic Plaque-type Psoriasis

United States, Hungary, Italy, Russian Federation, Germany, Czechia, Canada
Novartis Pharmaceuticals

Completed

Plaque Psoriasis Efficacy and Safety With Secukinumab (OPTIMISE)

Plaque Psoriasis

Germany, Belgium, Spain, Croatia, Czechia, Greece, Hungary, Russian Federation, Netherlands, Austria, France, Switzerland, Israel, United Kingdom, Italy, Lithuania, Sweden, Bulgaria, Denmark, Finland, Portugal, Slovakia, Poland, Latvia
Janssen Research & Development, LLC

Completed

A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)

Psoriasis

France, Ukraine, United Kingdom, Germany, Portugal, Canada, Belgium, Russian Federation, Hungary, Sweden
Boehringer Ingelheim

Completed

The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis

Psoriasis

United States, Poland, Hungary, Germany, Latvia, Russian Federation, Ukraine
Novartis Pharmaceuticals

Completed

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Moderate to Severe Plaque-type Psoriasis

Germany, United States, Belgium, Colombia, Spain, Estonia, Hungary, Japan, Lithuania, Taiwan, Australia, Korea, Republic of, Canada, Singapore, Italy, Israel, Sweden, Guatemala, United Kingdom, Argentina, France, Poland, Latvia, Iceland, Finla... and more
Pfizer

Completed

Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept

Psoriasis

Italy, France, Spain, Germany, Greece, Finland, Netherlands, Sweden, Norway, Belgium, Denmark, Hungary
AbbVie

Active, not recruiting

Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis (VALUE)

Chronic Plaque Psoriasis

Argentina, Australia, Austria, Canada, Colombia, Czechia, France, Germany, Hungary, Ireland, Italy, Japan, Mexico, Netherlands, Poland, Romania, Saudi Arabia, Spain, Switzerland, United Arab Emirates, United Kingdom
Janssen-Cilag International NV

Completed

A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate (TRANSIT)

Psoriasis

France, Germany, Poland, United Kingdom, Spain, Belgium, Portugal, Bulgaria, Greece, Israel, Sweden, Netherlands, Austria, Hungary, Lithuania, Slovakia, Denmark, Finland, Norway
Sanofi

Recruiting

A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis (SPECIFI-PSO)

Psoriasis

Chile, Germany, Mauritius, Japan, Canada, United States, Georgia, Turkey, Spain, Czechia, Hungary, Poland, Portugal, United Kingdom, China, Argentina
Bond Avillion 2 Development LP
Avillion LLP

Completed

A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis

Psoriasis

United States, Germany, Bulgaria, Canada, Czechia, Hungary, Poland
Actelion

Completed

ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis

Austria, Belgium, Bulgaria, Czechia, Denmark, France, Hungary, Italy, Lithuania, Romania, Russian Federation, Slovakia, Spain, Sweden, Switzerland, Ukraine, United Kingdom
Aristea Therapeutics, Inc.

Terminated

A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

Palmoplantar Pustulosis

United States, Canada, Germany, Poland, Czechia, Hungary, United Kingdom
Amgen

Completed

A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

United States, Poland, Canada, Germany, Estonia, Georgia, Hungary, Latvia
Janssen Research & Development, LLC

Completed

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (VOYAGE 1)

Psoriasis

United States, Australia, Taiwan, Germany, Spain, Korea, Republic of, Canada, Russian Federation, Poland, Hungary
Pfizer

Completed

Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis

Psoriasis

United States, Germany, Canada, Denmark, Hungary, Australia, Latvia, Poland, Bulgaria, Japan
Eli Lilly and Company

Completed

A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) (UNCOVER-3)

Psoriasis

United States, Hungary, Germany, Canada, Mexico, Bulgaria, Russian Federation, Poland, Argentina, Chile
Eli Lilly and Company

Completed

A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-1)

Psoriasis

Italy, United States, Australia, Germany, Canada, Denmark, Japan, Poland, Hungary, Romania, United Kingdom
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis

Psoriasis

Belgium, France, Germany, Italy, Spain, United Kingdom, Switzerland, Greece, Netherlands, Sweden, Austria, Hungary, Denmark, Norway, Portugal, Turkey, Czech Republic, Finland, Poland
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis (ECLIPSE)

Psoriasis

United States, Germany, France, Hungary, Czechia, Canada, Spain, Australia, Poland
Boehringer Ingelheim

Terminated

A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab

Palmoplantar Pustulosis

United Kingdom, Korea, Republic of, United States, Canada, Belgium, Australia, Taiwan, Japan, France, Germany, Russian Federation, Czechia, Hungary, Poland
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis (POETYK-PSO-2)

Psoriasis

United States, Spain, Hungary, Australia, Germany, Canada, Czechia, Poland, Puerto Rico, Finland, France, Israel, Italy, New Zealand, Sweden, United Kingdom
Eli Lilly and Company

Completed

A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

Psoriasis

United States, Spain, Puerto Rico, Canada, France, Korea, Republic of, Australia, Italy, Israel, Japan, Germany, Argentina, Czechia, Hungary, Poland, United Kingdom
Pfizer

Completed

A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

United States, Canada, Germany, Colombia, Hungary, Japan, Mexico, Poland, Serbia, Taiwan, Ukraine
Eli Lilly and Company

Terminated

A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

Psoriasis

United States, Spain, Puerto Rico, Canada, France, Korea, Republic of, Germany, Australia, Italy, Israel, Poland, Japan, Argentina, Hungary, Taiwan, United Kingdom, Mexico, Czechia, Russian Federation
Pfizer

Completed

A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

United States, Canada, Poland, Serbia, Germany, Ukraine, Taiwan, Mexico, Colombia, Hungary, Puerto Rico
Bristol-Myers Squibb

Active, not recruiting

Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE)

Psoriasis

China, Taiwan, Spain, United States, Hungary, Canada, Germany, Japan, Australia, Poland, Czechia, United Kingdom, Korea, Republic of, Israel, New Zealand, Sweden, France, Finland, Russian Federation, Puerto Rico
Pfizer

Completed

A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

Belgium, Spain, Germany, France, Hungary, Russian Federation, Singapore, Argentina, Austria, Bosnia and Herzegovina, Bulgaria, Chile, Colombia, Croatia, Czechia, Denmark, Hong Kong, Israel, Korea, Republic of, Netherlands, Poland, Slovaki... and more
Pfizer

Terminated

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

United States, Spain, Korea, Republic of, Taiwan, Canada, Poland, Belgium, Denmark, Germany, Serbia, United Kingdom, France, Czechia, Hungary, Mexico, Colombia, Russian Federation, Croatia, Singapore, Australia, Austria, Slovakia, S... and more
Boehringer Ingelheim

Completed

A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis

Palmoplantar Pustulosis (PPP)

United Kingdom, Korea, Republic of, United States, Canada, Belgium, Australia, Taiwan, Japan, France, Germany, Russian Federation, Hungary, Netherlands, Czechia, Poland
Centocor, Inc.
Centocor BV

Completed

A Long-term Safety Study of Infliximab (Remicade)

Arthritis, Rheumatoid | Psoriasis | Crohn Disease

United States, Canada, France, Germany, Poland, United Kingdom, Belgium, Spain, Argentina, Israel, Switzerland, Finland, Sweden, Netherlands, Austria, Hungary, Ireland, Norway, Denmark

Clinical Trials on Psoriatic Nail in Hungary

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations